Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.
Guide · Peptides · United States
BPC-157 prescriptions in the US: what HHS changed, what it costs and where to get it
Yes, within limits. Under an interim policy announced on October 28, 2026 (published in the Federal Register on October 30), HHS does not intend to take enforcement action against a state-licensed US pharmacy that compounds BPC-157 for an individual prescription, as the only active ingredient, by injection, by mouth or on the skin. BPC-157 is still not FDA approved, blends and “research use only” products are outside the policy, and HHS may revisit it.[1][2] This guide sets out what changed and when, the six peptides the policy covers and by which route, what it does not do, what a legitimate prescription looks like, what it costs, and where a US reader can get single-peptide BPC-157 today. It was checked on October 30, 2026.
BPC-157 in the US at a glance
- FDA statusNot approvedNo FDA-approved BPC-157 product exists; the HHS policy does not grant approval.[6][4]
- PrescriptionAllowed, under conditions503A compounding for one patient's prescription, single ingredient, from FDA-registered bulk ingredient.[2]
- BlendsNot coveredBPC-157 with TB-500, or with GHK-Cu and KPV, has more than one active ingredient.[2]
- Price we track$145 a monthLive Vital, single BPC-157, $289 every 2 months if prescribed (checked Oct 30, 2026).[7]
What changed, and when
In 2023 the FDA restricted compounding of BPC-157 and a group of other peptides over safety concerns, which Time describes as having “essentially banned” them.[5] In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides for compounding, BPC-157 among them, despite FDA staff advising against the move, as Time reports.[5]
On October 28, 2026 the HHS Office of the Secretary announced an interim policy of enforcement discretion for compounding six peptides under section 503A of the Federal Food, Drug, and Cosmetic Act, and it was published in the Federal Register on October 30, 2026 (Docket No. HHS-OASH-2026-0496). Written comments are accepted for two weeks after publication.[1] The policy covers state-licensed pharmacies, federal facilities and licensed physicians compounding under 503A.[3] HHS says the policy “does not grant FDA approval or establish clinical safety and effectiveness”, and that it may revisit the policy in whole or in part.[4][1]
The six peptides the policy covers, and the route for each
Appendix B lists one form and one or more routes for each peptide. A compounded product outside the listed route, or combining a listed peptide with any other active ingredient, is outside the policy.[2]
| Peptide | Form listed | Route covered | A provider we work with sells a covered form? |
|---|---|---|---|
| BPC-157 | BPC-157 acetate | Subcutaneous, intramuscular, oral or topical | Yes: Live Vital, single peptide |
| TB-500 | TB-500 | Subcutaneous or intramuscular injection compounded from the bulk ingredient | Yes: Live Vital, single peptide |
| MOTS-c | MOTS-c acetate | Subcutaneous or intramuscular injection | Yes: Live Vital, single peptide |
| Epitalon | Epitalon | Subcutaneous or intramuscular injection, dispensed in intermittent courses | Not yet (checked October 30, 2026) |
| Semax | Semax free base | Intranasal | Not yet (checked October 30, 2026) |
| KPV | KPV acetate | Topical and oral (not injection) | Not yet (checked October 30, 2026) |
Each peptide: what is covered, and whether anyone we list sells it
Routes are as Appendix B lists them; whether a provider sells a covered form was checked on October 30, 2026.[2]
BPC-157
Covered: BPC-157 acetate on its own, by subcutaneous or intramuscular injection, by mouth (with documentation of adequate bioavailability) or on the skin. Who we list: Live Vital sells it as a single peptide. Its blends that contain BPC-157 (Wolverine, Klow) are outside the policy. What it is, the research and side effects: BPC-157 peptide.
TB-500
Covered: TB-500 on its own, as a subcutaneous or intramuscular injection compounded from the bulk ingredient. Who we list: Live Vital sells it as a single peptide. A BPC-157 and TB-500 blend is outside the policy. What it is, the research and side effects: TB-500 peptide.
MOTS-c
Covered: MOTS-c acetate on its own, as a subcutaneous or intramuscular injection. Who we list: Live Vital sells it, on its own product page. What it is, the research and side effects: MOTS-c peptide.
Epitalon
Covered: Epitalon on its own, as a subcutaneous or intramuscular injection dispensed in intermittent courses. Who we list: No provider we list sells it. What it is, the research and side effects: Epitalon peptide.
Semax
Covered: Semax free base on its own, intranasal only. Who we list: No provider we list sells single-ingredient intranasal Semax. REBL lists a Semax + Selank product, which, as a two-ingredient product, is outside the policy. What it is, the research and side effects: Semax peptide.
KPV
Covered: KPV acetate on its own, topical or oral (with documentation of adequate bioavailability); not by injection. Who we list: No provider we list sells a covered form. Live Vital's only KPV product is the Klow blend (GHK-Cu, KPV, BPC-157 and TB-500), which as a multi-ingredient product is outside the policy. What it is, the research and side effects: KPV peptide.
What the policy does not do
- It does not approve BPC-157 or any of the six. HHS says it does not grant FDA approval or establish clinical safety and effectiveness.[4]
- It does not cover blends. A compounded product may contain only a single active ingredient from the list, so BPC-157 with TB-500, or blends that add GHK-Cu or KPV, are outside it.[2]
- It does not cover “research chemical” products, dietary supplements or 503B outsourcing facilities.[3]
- It is not permanent. It is an interim policy that HHS says it may revisit in whole or in part.[1]
- It says nothing about whether BPC-157 works. The research behind it is mostly animal and laboratory studies, and robust human trials are lacking. Time describes the benefits of these peptides as “largely scientifically unproven”.[5]
How to tell a legitimate prescription from a “research use only” seller
Appendix B sets the conditions a compounded product has to meet. Each is something you can ask about before paying.[2]
- A licensed clinician reviews you and writes a prescription for you, by name. No prescription, no policy.
- A state-licensed pharmacy compounds it, from bulk ingredient made by an FDA-registered, CGMP manufacturer with a valid certificate of analysis.
- The product contains BPC-157 and nothing else that is active.
- The label says “This is a compounded drug product. Not for resale.”
- An oral form comes with documentation of its bioavailability, and the only device packed with an injectable is an FDA 510(k)-cleared syringe.
- Serious adverse events are reported to FDA's MedWatch and to the states where the product was compounded and sent.
A website selling vials “for research purposes only” or “not for human consumption”, with no clinician and no prescription, meets none of these, and the policy does not cover it.[3]
What a BPC-157 prescription costs
Time reported that telehealth sites were marketing the six peptides at $199 to $249 a month shortly after the announcement.[5] That is a reported range, not a price we read. The single-peptide BPC-157 price we track, below, is under the low end of that range.
The price we track, read from the provider's own page: BPC-157 on its own (not a blend): $145 a month, charged $289 every 2 months on a subscription that renews automatically, if prescribed (checked Oct 30, 2026).[7] For the same provider's other covered peptides: TB-500 on its own (not a blend): $165 a month, charged $329 every 2 months on a subscription that renews automatically, if prescribed (checked Oct 30, 2026). MOTS-c: from $200 a month, charged $399 every 2 months on a subscription that renews automatically, if prescribed (checked Oct 30, 2026). Check the total of the first charge, which covers two months, and how to cancel before the renewal date.
Where to get single-peptide BPC-157 in the US
Of the US telehealth providers we work with, Live Vital is the one that sells BPC-157 as a single peptide. It says every treatment requires a medical intake and review by a licensed clinician, names a physician (Dr. Patrick Taylor, MD), and lists all 50 states. Live Vital says its peptides are compounded by a licensed US pharmacy. Compounded peptides are not FDA approved, and the FDA has not evaluated them for safety or effectiveness. We have not seen its pharmacy documentation and cannot confirm each policy condition for each order, and we found no BBB profile and could not read its Trustpilot page on October 30, 2026. Live Vital also sells blends; we do not link to their own pages, because they are outside the policy. Our Live Vital review has the detail.
US only. A prescription is a clinician's decision and is never guaranteed. This is not a recommendation to use BPC-157, and this page gives no dosing information.
Each button opens Live Vital's own page for that peptide: BPC-157, TB-500 or MOTS-c.
BPC-157 and TB-500 together
Both peptides are on the list, but only one at a time: a vial that blends them has two active ingredients and is outside the policy.[2] Two separate single-peptide prescriptions are a different matter, and a clinician would decide whether either is appropriate. Our BPC-157 vs TB-500 comparison sets out how the two differ, and the reference pages on BPC-157 and TB-500 cover the evidence and the sport bans: TB-500 is prohibited at all times, and BPC-157 falls under the World Anti-Doping Agency's non-approved substances category.
Reading this in the UK or Ireland?
The HHS policy is US only and changes nothing in the UK or Ireland, where BPC-157 is not a licensed medicine. Our guide to whether BPC-157 is legal in the UK and Ireland covers the MHRA and HPRA position and how a clinician can be involved.
Frequently asked questions
Is BPC-157 FDA approved?
No. No FDA-approved BPC-157 product exists. The interim HHS policy of October 28, 2026 is enforcement discretion for pharmacy compounding, and HHS says it does not grant FDA approval or establish clinical safety and effectiveness.
Is BPC-157 legal in the US now?
Compounded BPC-157 can be prescribed and dispensed in the US within limits. Under an interim policy announced on October 28, 2026 (published in the Federal Register on October 30), HHS does not intend to take enforcement action against a state-licensed pharmacy, a federal facility or a licensed physician compounding BPC-157 acetate under section 503A for an individual prescription, as the only active ingredient, if the policy's conditions are met. That is non-enforcement under an interim policy that HHS may revisit, not a change in the law and not FDA approval. It does not cover 503B outsourcing facilities, 'research chemical' products or dietary supplements.
Can I get a BPC-157 prescription online?
Yes, from a US telehealth service whose clinician decides it is appropriate and whose state-licensed pharmacy compounds it. A prescription is a clinician's decision and is never guaranteed. Compounded BPC-157 is not FDA approved, and the evidence for it is mostly from animal and laboratory studies.
How much does a BPC-157 prescription cost?
At Live Vital, the one provider we work with that sells it as a single peptide, $145 a month, charged $289 every 2 months on a subscription that renews automatically, if prescribed (checked Oct 30, 2026). Time reported telehealth sites marketing the six covered peptides at $199 to $249 a month shortly after the announcement, so Live Vital's price is below that range.
Is a BPC-157 and TB-500 blend covered?
No. The policy covers a compounded product only if it contains a single active ingredient from the list, so a BPC-157 and TB-500 blend (sometimes sold as 'Wolverine') or a blend adding GHK-Cu or KPV is outside it. BPC-157 and TB-500 are each covered on their own; GHK-Cu is not on the list, and KPV is covered only in topical or oral forms.
Is 'research use only' BPC-157 legal to buy?
The HHS policy does not cover it. Research chemicals labeled 'not for human use' are not compounded for a patient, not dispensed on a prescription and not made to the policy's conditions, so the policy gives them no cover, and their identity, purity and dose are unverified.
Where can I buy BPC-157?
The route the HHS policy covers is a prescription: a licensed US clinician orders it and a state-licensed pharmacy compounds it for you. We link to one provider that sells single-peptide BPC-157 that way, and to no research-chemical seller.
Does this change anything in the UK or Ireland?
No. The HHS policy is US only. No current UK marketing authorization was found for BPC-157 in the MHRA Products register, and no BPC-157 product appears on Ireland's HPRA list of authorized medicines.
Sources
Each numbered reference in the text points to one of these. The date is the day we read the source.
- HHS Office of the Secretary, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances", Docket No. HHS-OASH-2026-0496, RIN 0910-ZD94, Federal Register public inspection copy (published October 30, 2026). public-inspection.federalregister.gov. Read October 30, 2026.
- HHS, 503A peptide enforcement discretion policy, Appendix B: the conditions and the covered route for each peptide. www.hhs.gov. Read October 30, 2026.
- Baker Hostetler, "HHS Issues Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (who is and is not covered). www.bakerlaw.com. Read October 30, 2026.
- AJMC, "5 Things to Know About HHS's Interim Peptide Compounding Policy". www.ajmc.com. Read October 30, 2026.
- Time, "The Peptide Rush Has Begun", October 28, 2026. time.com. Read October 30, 2026.
- Drugs@FDA (openFDA): no approved product matching BPC-157. api.fda.gov. Read October 30, 2026.
- Live Vital, BPC-157 treatment page (price, billing every 2 months, if prescribed, licensed US pharmacy). www.livevital.io. Read October 30, 2026.
This page is information, not medical or legal advice. It does not recommend BPC-157 or any other peptide, and it gives no dosing guidance. Talk to a licensed clinician about what is appropriate for you.